Digestive Diseases and Sciences

, Volume 56, Issue 9, pp 2711–2714 | Cite as

A Rare Presentation of an Uncommon Malignancy: Thromboembolism in a Patient with a Gastrointestinal Stromal Tumor

  • Marisa Kardos
  • Andrew Lundquist
  • Michael Misialek
  • Lawrence S. Friedman
Case Report

Gastrointestinal stromal tumors (GISTs) are uncommon, with an annual incidence of 10–20 per 106 persons [1]. GISTs usually arise from mutations in the c-KIT receptor [2]. Approximately 50–60% occur in the stomach and often present as an abdominal mass, pain, or gastrointestinal (GI) bleeding [1]. We describe a patient who presented with deep vein thrombosis (DVT) and pulmonary embolism (PE) and was found to have a GIST.


A 48-year-old man presented to the emergency department with left leg pain and dyspnea on exertion that began 1 week earlier. He denied weight loss, abdominal pain, fever, or chills but reported occasional dark bowel movements. He had no history of blood clots, recent travel, or prolonged immobility.

On examination, he was afebrile, pale, and diaphoretic, with a heart rate of 116/min, blood pressure of 126/66 mm Hg, and last recorded body mass index was 28.9. Examination of the left lower extremity was notable for erythema, non-pitting edema, and tenderness to...


GIST Gastrointestinal stromal tumor Thromboembolism Deep vein thrombosis Pulmonary embolism Malignancy 


Conflict of interest

There are no financial arrangements or conflicts of interest to be declared.


  1. 1.
    Katz SC, DeMatteo RP. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol. 2008;97:350–359.PubMedCrossRefGoogle Scholar
  2. 2.
    Rubin B, Heinrich M, Corless C. Gastrointestinal stromal tumor. Lancet. 2007;369:1731–1741.PubMedCrossRefGoogle Scholar
  3. 3.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Heit JA, O’Fallon WM, Peterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–1248.PubMedCrossRefGoogle Scholar
  5. 5.
    Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–862.PubMedGoogle Scholar
  6. 6.
    Kasthuri R, Taubman M, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27:4834–4838.PubMedCrossRefGoogle Scholar
  7. 7.
    Winter P. The pathogenesis of venous thromboembolism in cancer: emerging links with tumor biology. Hematol Oncol. 2006;24:126–133.PubMedCrossRefGoogle Scholar
  8. 8.
    Melichar B, Laco J, Slovácek L, et al. Fatal venous thromboembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor. J Exp Clin Cancer Res. 2006;25:607–610.PubMedGoogle Scholar
  9. 9.
    Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Hemostasis. 2010;8:540–547.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Marisa Kardos
    • 1
    • 2
    • 6
  • Andrew Lundquist
    • 3
  • Michael Misialek
    • 4
  • Lawrence S. Friedman
    • 1
    • 2
    • 3
    • 5
  1. 1.Department of MedicineNewton-Wellesley HospitalNewtonUSA
  2. 2.Tufts University School of MedicineBostonUSA
  3. 3.Department of MedicineMassachusetts General HospitalBostonUSA
  4. 4.Department of PathologyNewton-Wellesley HospitalNewtonUSA
  5. 5.Harvard Medical SchoolBostonUSA
  6. 6.NewtonUSA

Personalised recommendations